Polypeptides in treatment of patients with obliterating atherosclerosis of the arteries lower extremities
https://doi.org/10.21518/akh2025-006
Abstract
Introduction. Treatment of patients with chronic lower limb ischemia against the background of obliterating atherosclerosis should be aimed at restoring the impaired hemodynamics of the vascular bed. In atherosclerosis, a violation of the peptide composition leads to a decrease in the ability of the vascular wall to prevent the development of pathological processes.
Aim. To evaluate the efficacy and safety of using a drug based on bovine vascular polypeptides in patients with obliterating atherosclerosis of the lower limb arteries.
Materials and methods. 105 patients with chronic lower limb ischemia of grades IIA and IIB against the background of obliterating atherosclerosis. There were 96 men and 9 women, the average age was 60 ± 5.6 and 70 ± 3.8 years, respectively. All patients received conservative treatment. In the 1st group (n = 34) additionally – cilostazol; in the 2nd group (n = 35) – additionally sulodexide; in the 3rd (main) group (n = 36) – additionally – sulodexide according to the above scheme and Polipeptydi.
Results. After 3 months from the start of treatment, a good therapeutic effect was maintained in all groups. After 6 months, negative dynamics were noted in the 1st and 2nd groups of patients. Repeated courses of conservative treatment were required. These patients were excluded from further study. In the 3rd group (Polipeptyd + sulodexide), the therapeutic effect was maintained for 9 months from the start of treatment.
Discussion. If it is impossible to reconstruct arterial blood flow, it is necessary to prescribe drugs that increase the rheological properties of the blood, improve direct blood flow in the affected limb, and also have a positive effect on metabolism.
Conclusions. The inclusion of Polipeptydm, a peptide regulator, in the complex conservative treatment of patients with obliterating atherosclerosis of the arteries of the extremities allows for an increase in its effectiveness and a significant prolongation of the positive therapeutic result.
About the Authors
E. P. Krivoshchekov
Samara State Medical University
Russian Federation
Russian Federation
Evgeny P. Krivoshchekov, Dr. Sci. (Med.), Professor, Professor of the Department of Surgery of the Institute of Postgraduate Education,
89, Chapaevskaya St., Samara, 443099
S. E. Katorkin
Samara State Medical University
Russian Federation
Russian Federation
Sergei E. Katorkin, Dr. Sci. (Med.), Professor, Head of Department and Hospital Surgery Clinic,
89, Chapaevskaya St., Samara, 443089
References
1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;45(1):5–67. https://doi.org/10.1016/j.jvs.2006.12.037.
2. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R et al. Global vascular guidelines on the management of chronic limbthreatening ischemia. J Vasc Surg. 2019;69(6):3–125. https://doi.org/10.1016/j.jvs.2019.02.016.
3. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239–1312. https://doi.org/10.1016/j.jacc.2005.10.009.
4. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;69(11):71–126. https://doi.org/10.1016/j.jacc.2016.11.008.
5. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–1340. https://doi.org/10.1016/S0140-6736(13)61249-0.
6. Kharazov AF, Kalyev AO, Isaev AA. PAD prevalence in Russian Federation. Pirogov Russian Journal of Surgery. 2016;(7):58–61. (In Russ.) https://doi.org/10.17116/hirurgia2016758-61.
7. Бокерия ЛА, Покровский АВ, Акчурин РС, Алекян БГ, Апханова ТВ, Аракелян ВС и др. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. М.; 2019. 89 с. Режим доступа: https://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.рdf.
8. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3):2–41. https://doi.org/10.1016/j.jvs.2014.12.009.
9. Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E et al. Cost-eff ectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vasc Med. 2018;23(2):97–106. https://doi.org/10.1177/1358863X17745371.
10. Patel KK, Jones PG, Ellerbeck EF, Buchanan DM, Chan PS, Pacheco CM et al. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry. J Am Heart Assoc. 2018;7(20):010076. https://doi.org/10.1161/JAHA.118.010076.
11. Foley TR, Singh GD, Kokkinidis DG, Choy HK, Pham T, Amsterdam EA et al. High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc. 2017;6(7):e005699. https://doi.org/10.1161/JAHA.117.005699.
12. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338–350. https://doi.org/10.1161/circulationaha.117.032235.
13. Piepoli MF, Hoes AW, Agewall S, Albus Ch, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106.
14. Hess CN, Hiatt WR. Antithrombotic therapy for peripheralartery diseasein 2018. JAMA. 2018;319(22):2329–2330. https://doi.org/10.1001/jama.2018.5422.
15. Asal NJ, Wojciak RA. Effect of cilostazol in treating diabetesassociated microvascular complications. Endocrine. 2017;56(2):240–244. https://doi.org/10.1007/s12020-017-1279-4.
16. Krivoshchekov EP, Elshin EB, Ganja NF, Romanov VE. Modern pathogenetic therapy of diabetic foot wounds. Sciences of Europe. 2018;1(25):37–40. (In Russ.) Available at: https://www.europe-science.com/wp-content/uploads/2020/10/VOL-1-No-25-2018.pdf.
17. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES et al. Comparative effi cacy of endovascular revascularization versus supervised exercise training in patients with intermittent claudication: meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2017;10(7):712–724. https://doi.org/10.1016/j.jcin.2017.01.027.
18. Wiseman JT, Fernandes-Taylor S, Saha S, Havlena J, Rathouz PJ, Smith MA et al. Endovascular versus open revascularization for peripheral arterial disease. Ann Surg. 2017;265(2):424–430. https://doi.org/10.1097/SLA.0000000000001676.
19. Barrett C, Barshes NR, Corriere MA. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease. Circulation. 2017;135:686–725. https://doi.org/10.1161/CIR.0000000000000471.
20. Khryshchanovich V. Diagnosis and Management of Peripheral Artery Diseases. Kardiologija v Belarusi. 2020;12(3):390–408. (In Russ.) https://doi.org/10.34883/PI.2020.12.3.009.
21. Kotelnikov GP, Losev II, Sizonenko YV, Katorkin SE. Peculiarities of diagnostics and treatment tactics of patients with combined lesion of the musculoskeletal and venous systems of the lower limbs. Novosti Khirurgii. 2013;21(3):42–53. (In Russ.) Available at: https://core.ac.uk/download/pdf/53875487.pdf
22. Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665–673. https://doi.org/ 10.1038/hr.2011.39.
23. Majumder K, Chakrabarti S, Davidge ST, Wu J. Structure and activ-ity study of egg protein ovotransferrin derived peptides (IRW and IQW) on endothelial inflammatory response and oxidative stress. J Agric Food Chem. 2013;61:2120–2129. https://doi.org/10.1021/jf3046076.
24. Huang W, Chakrabarti S, Majumder K, Jiang Y, Davidge ST, Wu J. Egg-derived peptide IRW inhibits TNF-alpha-induced inflammatory responseand oxidative stress in endothelial cells. J Agric Food Chem. 2010;58(20):10840–10846. https://doi.org/10.1021/jf102120c.
25. Demidova-Rice TN, Geevarghese A, Herman IM. Bioactive peptides derived from vascular endothelial cell extracellular matrices promote microvascular morphogenesis and wound healing in vitro. Wound Repair Regen. 2011;19(1):59–70. https://doi.org/10.1111/j.1524-475X.2010.00642.x.
26. Vo TS, Kim SK. Down-regulation of histamine-induced endothelial cell activation as potential anti-atherosclerotic activity of peptides from Spir-ulina maxima. Eur J Pharm Sci. 2013;50:198–207. https://doi.org/10.1016/j.ejps.2013.07.001.
27. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71(20):2306–2315. https://doi.org/10.1016/j.jacc.2018.03.008.
28. Smolderen KG, Gosch K, Patel M, Jones WS, Hirsch AT, Beltrame J et al. PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): overview of design and rationale of an international prospective peripheral arterial disease study. Circ Cardiovasc Qual Outcomes. 2018;11(2):e003860. https://doi.org/10.1161/CIRCOUTCOMES.117.003860.
29. Gavrilenko AV, Skrylev SI, Kuzubova EA. Modern possibilities and prospects of surgical treatment of patients with critical lower limb ischemia. Angiology and Vascular Surgery. 2002;8(4):80–86. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2002/4/13.htm.
30. Katelnitsky II, Muratov AM, Alukhanyan OA. Results of modern methods of restoring blood flow in critical ischemia in patients with atherosclerotic lesion of the lower leg arteries. Kuban Scientific Medical Bulletin. 2016;(5):76–80. (In Russ.) https://doi.org/10.25207/1608-6228-2016-5-76-80.
31. Kuznetsov MR, Reshetov IV, Sapelkin SV, Yasnopolskaya NV. Conservative treatment of patients with intermittent claudication. RMJ. Medical Review. 2021;5(4):212–217. (In Russ.) https://doi.org/10.32364/2587-6821-2021-5-4-212-217.
32. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T et al. Editor’s Choice – 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305–368. https://doi.org/10.1016/j.ejvs.2017.07.018.
33. Malgor RD, Alahdab F, Elraiyah TA, Rizvi AZ, Lane MA, Prokop LJ et al. A systematic review of treatment of intermittent claudication in thelower extremities. J Vasc Surg Elsevier BV. 2015;61(3):54–73. https://doi.org/10.1016/j.jvs.2014.12.007.
34. Chervyakov YuV, Moskovsky IA. Results of outpatient treatment of patients with peripheral atherosclerosis of the arteries of the lower extremities. Ambulatornaya Khirurgiya. 2022;19(1):51–59. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-1-51-59.
35. Rybak Z. Effectiveness of cilostazol in the treatment of peripheral obstruction. Polskie Archiwum Medycyny Wewnetrznej. 2015;125(3):117–118. https://doi.org/10.20452/pamw.2699.
36. Kazantsev AN, Goryunov SV, Ershova OB, Erofeeva SB, Gurgenyan EV. Randomized study of the tolerability, safety and efficacy of the drug Pletax in intermittent lameness. Angiology and Vascular Surgery. 2021;27(1):7–16. (In Russ.) https://doi.org/10.33529/angio2020405.
37. Katorkin SE. Significance of endothelial protection in treatment of patients with class c6 chronic venous disease and type 2 diabetes mellitus. Angiology and Vascular Surgery. 2015;(3):99–105. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2015/3/12.htm.
38. Krivoschekov EP, Elshin EB, Romanov VE, Alyapyshev GS, Rodnyansky DV. Ways oflimb preservation in the postoperative period of treatment of complications of diabetic foot syndrome. Angiology and Vascular Surgery. 2020;26(4):33–41. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2020/4/5.htm.
Review
For citations:
Krivoshchekov E.P., Katorkin S.E. Polypeptides in treatment of patients with obliterating atherosclerosis of the arteries lower extremities. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2025;22(1):110-119. (In Russ.) https://doi.org/10.21518/akh2025-006
Views:
399
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 